Xiaomeng Jia

467 Zhongshan Road
Dalian, 116023, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Dual-responsive diazo probe for labeling of aggrephagic compartments in live cells.

Dual-responsive diazo probe for labeling of aggrephagic compartments in live cells.

Journal: Talanta
Published: August 31, 2025

Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine.

Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine.

Journal: Frontiers in bioscience (Landmark edition)
Published: August 23, 2025

Optimizing endocrine adjuvant therapy in HR+/HER2- breast cancer: supplemental strategies and innovations.

Optimizing endocrine adjuvant therapy in HR+/HER2- breast cancer: supplemental strategies and innovations.

Journal: Annals of medicine and surgery (2012)
Published: May 15, 2025

Acid-Resistant and Viscosity-Sensitive Proteome Aggregation Sensor To Visualize Cellular Aggrephagy in Live Cells and Clinical Samples.

Acid-Resistant and Viscosity-Sensitive Proteome Aggregation Sensor To Visualize Cellular Aggrephagy in Live Cells and Clinical Samples.

Journal: ACS sensors
Published: April 07, 2025

Options after progression on first-line CDK4/6 inhibitors in advanced breast cancer patients.

Options after progression on first-line CDK4/6 inhibitors in advanced breast cancer patients.

Journal: Therapeutic advances in medical oncology
Published: November 19, 2024

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes.

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes.

Journal: Breast (Edinburgh, Scotland)
Published: July 08, 2024

PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.

PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Journal: Clinical breast cancer
Published: September 11, 2023

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: July 05, 2022

Analysis of Risk Factors for Adjacent Segment Degeneration after Minimally Invasive Transforaminal Interbody Fusion at Lumbosacral Spine.

Analysis of Risk Factors for Adjacent Segment Degeneration after Minimally Invasive Transforaminal Interbody Fusion at Lumbosacral Spine.

Journal: Computational intelligence and neuroscience
Published: January 08, 2022

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation.

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation.

Journal: OncoTargets and therapy
Published: August 18, 2021
Showing 1-10 of 10

Last Updated: 09/26/2026